Literature DB >> 29317776

Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications.

Chun-Ming Wong1,2, Felice Ho-Ching Tsang1,2, Irene Oi-Lin Ng1,2.   

Abstract

Hepatocellular carcinoma (HCC) is a leading lethal malignancy worldwide. However, the molecular mechanisms underlying liver carcinogenesis remain poorly understood. Over the past two decades, overwhelming evidence has demonstrated the regulatory roles of different classes of non-coding RNAs (ncRNAs) in liver carcinogenesis related to a number of aetiologies, including HBV, HCV and NAFLD. Among the ncRNAs, microRNAs, which belong to a distinct class of small ncRNAs, have been proven to play a crucial role in the post-transcriptional regulation of gene expression. Deregulation of microRNAs has been broadly implicated in the inactivation of tumour-suppressor genes and activation of oncogenes in HCC. Modern high-throughput sequencing analyses have unprecedentedly identified a very large number of non-coding transcripts. Divergent groups of long ncRNAs have been implicated in liver carcinogenesis through interactions with DNA, RNA or proteins. Overall, ncRNAs represent a burgeoning field of cancer research, and we are only beginning to understand the importance and complicity of the ncRNAs in liver carcinogenesis. In this Review, we summarize the common deregulation of small and long ncRNAs in human HCC. We also comprehensively review the pathological roles of ncRNAs in liver carcinogenesis, epithelial-to-mesenchymal transition and HCC metastasis and discuss the potential applications of ncRNAs as diagnostic tools and therapeutic targets in human HCC.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29317776     DOI: 10.1038/nrgastro.2017.169

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  193 in total

1.  MicroRNA-148a suppresses the epithelial-mesenchymal transition and metastasis of hepatoma cells by targeting Met/Snail signaling.

Authors:  J-P Zhang; C Zeng; L Xu; J Gong; J-H Fang; S-M Zhuang
Journal:  Oncogene       Date:  2013-09-09       Impact factor: 9.867

2.  Sequential alterations of microRNA expression in hepatocellular carcinoma development and venous metastasis.

Authors:  Chun-Ming Wong; Carmen Chak-Lui Wong; Joyce Man-Fong Lee; Dorothy Ngo-Yin Fan; Sandy Leung-Kuen Au; Irene Oi-Lin Ng
Journal:  Hepatology       Date:  2012-05       Impact factor: 17.425

3.  The liver-specific microRNA-122*, the complementary strand of microRNA-122, acts as a tumor suppressor by modulating the p53/mouse double minute 2 homolog circuitry.

Authors:  Alina Simerzin; Elina Zorde-Khvalevsky; Mila Rivkin; Revital Adar; Jessica Zucman-Rossi; Gabrielle Couchy; Tania Roskams; Olivier Govaere; Moshe Oren; Hilla Giladi; Eithan Galun
Journal:  Hepatology       Date:  2016-07-25       Impact factor: 17.425

4.  Competing and noncompeting activities of miR-122 and the 5' exonuclease Xrn1 in regulation of hepatitis C virus replication.

Authors:  You Li; Takahiro Masaki; Daisuke Yamane; David R McGivern; Stanley M Lemon
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-17       Impact factor: 11.205

5.  Epigenetic modification of MiR-429 promotes liver tumour-initiating cell properties by targeting Rb binding protein 4.

Authors:  Liang Li; Jing Tang; Baohua Zhang; Wen Yang; Miyang LiuGao; Ruoyu Wang; Yexiong Tan; Jianling Fan; Yanxin Chang; Jing Fu; Feng Jiang; Caiyang Chen; Yingcheng Yang; Jin Gu; Dingming Wu; Linna Guo; Dan Cao; Hengyu Li; Guangwen Cao; Mengchao Wu; Michael Q Zhang; Lei Chen; Hongyang Wang
Journal:  Gut       Date:  2014-02-26       Impact factor: 23.059

6.  Interferon modulation of cellular microRNAs as an antiviral mechanism.

Authors:  Irene M Pedersen; Guofeng Cheng; Stefan Wieland; Stefano Volinia; Carlo M Croce; Francis V Chisari; Michael David
Journal:  Nature       Date:  2007-10-18       Impact factor: 49.962

7.  Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma.

Authors:  Laura Gramantieri; Manuela Ferracin; Francesca Fornari; Angelo Veronese; Silvia Sabbioni; Chang-Gong Liu; George A Calin; Catia Giovannini; Eros Ferrazzi; Gian Luca Grazi; Carlo M Croce; Luigi Bolondi; Massimo Negrini
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

8.  Upregulation of long noncoding RNA ZEB1-AS1 promotes tumor metastasis and predicts poor prognosis in hepatocellular carcinoma.

Authors:  T Li; J Xie; C Shen; D Cheng; Y Shi; Z Wu; X Deng; H Chen; B Shen; C Peng; H Li; Q Zhan; Z Zhu
Journal:  Oncogene       Date:  2015-06-15       Impact factor: 8.756

9.  Plasma HULC as a promising novel biomarker for the detection of hepatocellular carcinoma.

Authors:  Hui Xie; Hongwei Ma; Danqiu Zhou
Journal:  Biomed Res Int       Date:  2013-05-22       Impact factor: 3.411

10.  LncRNA SRA promotes hepatic steatosis through repressing the expression of adipose triglyceride lipase (ATGL).

Authors:  Gang Chen; Dongsheng Yu; Xue Nian; Junyi Liu; Ronald J Koenig; Bin Xu; Liang Sheng
Journal:  Sci Rep       Date:  2016-10-19       Impact factor: 4.379

View more
  152 in total

1.  miR-337-3p suppresses the proliferation and invasion of hepatocellular carcinoma cells through targeting JAK2.

Authors:  Xue-Liang Zuo; Zhi-Qiang Chen; Jun-Feng Wang; Jin-Guo Wang; Lin-Hu Liang; Juan Cai
Journal:  Am J Cancer Res       Date:  2018-04-01       Impact factor: 6.166

Review 2.  Small non-coding RNAs in human cancer: function, clinical utility, and characterization.

Authors:  Zhao Zhang; Jian Zhang; Lixia Diao; Leng Han
Journal:  Oncogene       Date:  2021-01-15       Impact factor: 9.867

Review 3.  Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma.

Authors:  Chongchong Wang; Juehua Jing; Li Cheng
Journal:  Invest New Drugs       Date:  2018-08-06       Impact factor: 3.850

Review 4.  Emerging roles for noncoding RNAs in female sex steroids and reproductive disease.

Authors:  Runju Zhang; Victoria Wesevich; Zhaojuan Chen; Dan Zhang; Amanda N Kallen
Journal:  Mol Cell Endocrinol       Date:  2020-07-12       Impact factor: 4.102

Review 5.  Extracellular miRNAs: From Biomarkers to Mediators of Physiology and Disease.

Authors:  Marcelo A Mori; Raissa G Ludwig; Ruben Garcia-Martin; Bruna B Brandão; C Ronald Kahn
Journal:  Cell Metab       Date:  2019-08-22       Impact factor: 27.287

6.  Circular RNA 101368/miR-200a axis modulates the migration of hepatocellular carcinoma through HMGB1/RAGE signaling.

Authors:  Shaling Li; Huimin Gu; Yan Huang; Qian Peng; Rongrong Zhou; Panpan Yi; Ruochan Chen; Zebing Huang; Xingwang Hu; Yun Huang; Daolin Tang
Journal:  Cell Cycle       Date:  2018-10-22       Impact factor: 4.534

7.  Genome-wide analysis of prognostic-related lncRNAs, miRNAs and mRNAs forming a competing endogenous RNA network in lung squamous cell carcinoma.

Authors:  Qiang Ju; Yan-Jie Zhao; Sai Ma; Xin-Mei Li; Heng Zhang; Shao-Qiang Zhang; Yuan-Ming Yang; Song-Xia Yan
Journal:  J Cancer Res Clin Oncol       Date:  2020-04-30       Impact factor: 4.553

8.  The novel lncRNA CALIC upregulates AXL to promote colon cancer metastasis.

Authors:  Yoshihiro Kawasaki; Masaya Miyamoto; Takeaki Oda; Kosuke Matsumura; Lumi Negishi; Ryuichiro Nakato; Sakiko Suda; Naoko Yokota; Katsuhiko Shirahige; Tetsu Akiyama
Journal:  EMBO Rep       Date:  2019-07-29       Impact factor: 8.807

9.  Panel of potential lncRNA biomarkers can distinguish various types of liver malignant and benign tumors.

Authors:  Olga Y Burenina; Natalia L Lazarevich; Inna F Kustova; Daria A Shavochkina; Ekaterina A Moroz; Nikolay E Kudashkin; Yuriy I Patyutko; Alexey V Metelin; Eduard F Kim; Dmitry A Skvortsov; Timofei S Zatsepin; Maria P Rubtsova; Olga A Dontsova
Journal:  J Cancer Res Clin Oncol       Date:  2020-09-12       Impact factor: 4.553

10.  Long Noncoding RNA ITPRIP-1 Positively Regulates the Innate Immune Response through Promotion of Oligomerization and Activation of MDA5.

Authors:  Qinya Xie; Shengwen Chen; Renyun Tian; Xiang Huang; Rilin Deng; Binbin Xue; Yuwen Qin; Yan Xu; Jingjing Wang; Mengmeng Guo; Jinwen Chen; Songqing Tang; Guangdi Li; Haizhen Zhu
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.